it had signed a deal thought to be worth around $1 billion to research, develop and manufacture mRNA medicines in China.
But in response to a question from an executive from Merck, Li added: "You should also understand that our medical and social security systems and patients cannot cope with excessively high prices for new medications."
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: